Pharmaceutical

AbbVie acquires Cerevel Therapeutics for $8.7bn

AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.

Aug 3, 2024 - 04:00
AbbVie acquires Cerevel Therapeutics for $8.7bn
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
Read the original article

Tags:

Previous Article

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Next Article

AAIC 2024: Eisai presents positive long-term data with Leqembi

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A digital pill shows early promise in detecting opioid overdose, sleep apnea

STAT+: A digital pill shows early promise in detecting ...

Nov 17, 2023

No pain data yet from Vertex, and sky high deal expectations at JPM 2024

No pain data yet from Vertex, and sky high deal expecta...

Jan 8, 2024

AbbVie’s Q2 2024 net earnings drop to $1.37bn

AbbVie’s Q2 2024 net earnings drop to $1.37bn

Jul 28, 2024